Evaxion Biotech AS
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected mel… Read more
Evaxion Biotech AS (EVAX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.424x
Based on the latest financial reports, Evaxion Biotech AS (EVAX) has a cash flow conversion efficiency ratio of 0.424x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.01 Million) by net assets ($-4.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evaxion Biotech AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Evaxion Biotech AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Evaxion Biotech AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evaxion Biotech AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Equitable Financial Corp
PINK:EQFN
|
0.009x |
|
MKH Oil Palm (East Kalimantan) Berhad
KLSE:5319
|
0.065x |
|
Grupo Ezentis S.A
MC:EZE
|
-0.677x |
|
Goodway Machine Corp
TW:1583
|
-0.009x |
|
UIL Co. Ltd
KQ:049520
|
0.097x |
|
Burgenland Holding Aktiengesellschaft
VI:BHD
|
N/A |
|
MRM SA INH. EO 20
F:8VV0
|
N/A |
|
Global Crossing Airlines Inc
OTCQB:JETMF
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Evaxion Biotech AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Evaxion Biotech AS from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.65 Million | $-12.94 Million | 7.833x | +109.38% |
| 2023-12-31 | $-4.73 Million | $-17.69 Million | 3.741x | +220.51% |
| 2022-12-31 | $8.30 Million | $-25.77 Million | -3.104x | -359.08% |
| 2021-12-31 | $32.44 Million | $-21.93 Million | -0.676x | +61.74% |
| 2020-12-31 | $7.04 Million | $-12.44 Million | -1.767x | -135.48% |
| 2019-12-31 | $9.36 Million | $-7.03 Million | -0.750x | -135.09% |
| 2018-12-31 | $-931.00K | $-1.99 Million | 2.139x | -- |